Dr. Constantine A. Mantz, MD

Dr. Mantz practices at Genesiscare Usa of Florida in Cape Coral, Florida.

Dr. Mantz's NPI, 1396743290, was assigned on July 13, 2005. Dr. Mantz graduated from Pritzker School of Medicine in 1995. Dr. Mantz holds Florida license ME80838.

Dr. Mantz's primary practice is Genesiscare Usa of Florida, at 1419 SE 8th Ter, Cape Coral, FL 33990 in Lee County. The practice phone is (239) 489-3420.

Dr. Mantz's primary practice is Genesiscare Usa of Florida in Cape Coral, Florida. Dr. Mantz is also affiliated with Cape Coral Hospital. The medical group on file is GenesisCare. Dmand AI also links Dr. Mantz to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mantz practices, 4 sites in all. Vendor and product names are available with a free account.

Therapeutic radiology is Dr. Mantz's primary specialty in the NPI Registry, under taxonomy code 2085R0203X. Dr. Mantz is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Mantz's licenses on file in 3 states: Florida, Minnesota and Illinois.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation and head & neck cancer radiation among the conditions Dr. Mantz treats.

CMS data shows 17,815 Medicare services from Dr. Mantz across 41 procedure codes in 2024, for 734 Medicare patients. Medicare paid $3,328,004 for them.

CMS counts 734 Medicare patients who saw Dr. Mantz in 2024. The largest group is 75 to 84, with 329 patients. 75% of them have cancer, and 75% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mantz's median patient age at 76, with 20% women.

In 2024, Dr. Mantz wrote 608 Medicare Part D claims for 172 patients. 89% of them were for generic drugs. CMS names the drug for 461 of them, across 13 drugs with 11 or more claims each, at $637,552 in total drug cost. In 2023, CMS named 321 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Mantz for performance year 2024, reported individually. Dr. Mantz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mantz as offering telehealth.

Dmand AI links 39 papers to Dr. Mantz, published from 2010 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Medicare and Radiation Oncology. Dr. Mantz has published most often in Int J Radiat Oncol Biol Phys. Dr. Mantz's most frequent co-authors are Steven E. Finkelstein, MD, Howard M. Sandler, MD and Daniel E. Dosoretz, MD.

Dmand AI links Dr. Mantz to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 88 general payments to Dr. Mantz from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Accuray Incorporated paid the most, $4,634.

Dmand AI lists 2 awards for Dr. Mantz, most recently CMS Stage 1 EHR in 2014.

Dr. Mantz graduated from Pritzker School of Medicine in 1995.

Dr. Mantz is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.